Importin 3D structures

From Proteopedia

(Difference between revisions)
Jump to: navigation, search
Current revision (09:22, 18 September 2025) (edit) (undo)
 
Line 45: Line 45:
*''IPO-α 1 complex with NLS peptide''
*''IPO-α 1 complex with NLS peptide''
-
**[[4b18]] – hIPO NLS-binding domain + telomerase reverse transcriptase<br />
+
**[[2jdq]], [[4b18]] – hIPO NLS-binding domain + telomerase reverse transcriptase<br />
**[[4wv6]] – hIPO NLS-binding domain + TFIID<br />
**[[4wv6]] – hIPO NLS-binding domain + TFIID<br />
**[[6bw0]] – hIPO NLS-binding domain + Nipa virus peptide<br />
**[[6bw0]] – hIPO NLS-binding domain + Nipa virus peptide<br />
Line 55: Line 55:
**[[7n8j]] – hIPO NLS-binding domain + BIMAX peptide<br />
**[[7n8j]] – hIPO NLS-binding domain + BIMAX peptide<br />
**[[5h43]] – hIPO NLS-binding domain + histone acetyltransferase KAT8<br />
**[[5h43]] – hIPO NLS-binding domain + histone acetyltransferase KAT8<br />
 +
**[[8gcn]] – hIPO NLS-binding domain + IPO-beta 1 peptide – Cryo EM<br />
**[[8gai]] – IPO NLS-binding domain + BIMAX peptide – guinea pig<br />
**[[8gai]] – IPO NLS-binding domain + BIMAX peptide – guinea pig<br />
**[[4mz5]], [[4mz6]] – mIPO NLS-binding domain 70-528 + dUTPase<br />
**[[4mz5]], [[4mz6]] – mIPO NLS-binding domain 70-528 + dUTPase<br />
Line 90: Line 91:
**[[7rg4]], [[7rg5]] – mIPO NLS-binding domain + p50 peptide <br />
**[[7rg4]], [[7rg5]] – mIPO NLS-binding domain + p50 peptide <br />
**[[6wx7]] – mIPO NLS-binding domain + SOX2 peptide <br />
**[[6wx7]] – mIPO NLS-binding domain + SOX2 peptide <br />
 +
**[[8g8q]] – mIPO NLS-binding domain + monopartite p52 NLS + peptide<br />
 +
**[[8g8s]] – mIPO NLS-binding domain + bipartite p52 NLS peptide<br />
 +
**[[9cl8]], [[9cle]], [[9clf]], [[9clg]] – mIPO NLS-binding domain + zero net charge NLS peptide<br />
 +
**[[9y0r]] – mIPO NLS-binding domain + ATF2 peptide<br />
 +
**[[5fc8]], [[5hhg]], [[8vpr]], [[8vpu]] – mIPO NLS-binding domain + dengue virus peptide<br />
**[[4b8o]] – rIPO NLS-binding domain + SV40<br />
**[[4b8o]] – rIPO NLS-binding domain + SV40<br />
**[[4b8p]] – rIPO NLS-binding domain + A89<br />
**[[4b8p]] – rIPO NLS-binding domain + A89<br />
Line 101: Line 107:
**[[2jdq]] – hIPO NLS-binding domain + telomerase reverse transcriptase peptide<br />
**[[2jdq]] – hIPO NLS-binding domain + telomerase reverse transcriptase peptide<br />
**[[4uaf]] – mIPO NLS-binding domain + influenza RNA polymerase<br />
**[[4uaf]] – mIPO NLS-binding domain + influenza RNA polymerase<br />
 +
**[[8sg7]], [[9cft]] – mIPO NLS-binding domain + adeno-associated virus VP1<br />
*IPO-α 2
*IPO-α 2
Line 126: Line 133:
**[[3ve6]] – mIPO NLS-binding domain + Venezuelan equine encephalitis virus<br />
**[[3ve6]] – mIPO NLS-binding domain + Venezuelan equine encephalitis virus<br />
**[[8f2q]] – mIPO NLS-binding domain + parvovirus<br />
**[[8f2q]] – mIPO NLS-binding domain + parvovirus<br />
 +
**[[8q8k]], [[8sud]], [[8tuq]], [[8tur]], [[8tus]], [[8tut]], [[8tuu]], [[8tuv]] – mIPO NLS-binding domain + polyomavirus peptide<br />
 +
**[[8sv0]], [[8u36]] – mIPO NLS-binding domain + siadenovirus peptide<br />
 +
**[[8g8r]] – mIPO NLS-binding domain + RELB peptide<br />
**[[3uvu]] – mIPO NLS-binding domain + flap endonuclease<br />
**[[3uvu]] – mIPO NLS-binding domain + flap endonuclease<br />
**[[3ukw]], [[3ukx]] – mIPO NLS-binding domain + BIMAX<br />
**[[3ukw]], [[3ukx]] – mIPO NLS-binding domain + BIMAX<br />
Line 145: Line 155:
**[[6bvz]] – hIPO NLS-binding domain <br />
**[[6bvz]] – hIPO NLS-binding domain <br />
**[[4uae]] – hIPO NLS-binding domain + influenza RNA polymerase<br />
**[[4uae]] – hIPO NLS-binding domain + influenza RNA polymerase<br />
 +
**[[8qxx]] – hIPO NLS-binding domain + Herpes DNA polymerase processivity factor peptide<br />
 +
**[[8qxw]] – hIPO NLS-binding domain + cytomegalovirus DNA polymerase processivity factor peptide<br />
**[[6bw9]], [[6bwa]], [[6bwb]] – hIPO NLS-binding domain + Hendra virus peptide<br />
**[[6bw9]], [[6bwa]], [[6bwb]] – hIPO NLS-binding domain + Hendra virus peptide<br />
**[[6bvv]] – hIPO NLS-binding domain + Nipa virus peptide<br />
**[[6bvv]] – hIPO NLS-binding domain + Nipa virus peptide<br />
Line 186: Line 198:
**[[1ibr]] – hIPO + GTPase Ran<br />
**[[1ibr]] – hIPO + GTPase Ran<br />
**[[6n88]], [[6n89]] – hIPO + H1.0 – Cryo EM<br />
**[[6n88]], [[6n89]] – hIPO + H1.0 – Cryo EM<br />
 +
**[[9b4y]] – hIPO + IPO beta 1 peptide – Cryo EM<br />
**[[1f59]], [[1o6p]], [[1o6o]] – hIPO + FXFG nucleoporin repeats<br />
**[[1f59]], [[1o6p]], [[1o6o]] – hIPO + FXFG nucleoporin repeats<br />
**[[1m5n]] – hIPO HEAT repeats 1-11 + parathyroid hormone-related protein NLS peptide<br />
**[[1m5n]] – hIPO HEAT repeats 1-11 + parathyroid hormone-related protein NLS peptide<br />
Line 209: Line 222:
**[[5tqc]] – hIPO + RPL4 peptide<br />
**[[5tqc]] – hIPO + RPL4 peptide<br />
**[[5j3v]] – hIPO + histone H3 peptide<br />
**[[5j3v]] – hIPO + histone H3 peptide<br />
 +
**[[8sgh]] – hIPO NLS-binding domain + HNRNPH2 <br />
*IPO-β 3 (Karyopherin β 3)
*IPO-β 3 (Karyopherin β 3)
Line 224: Line 238:
**[[6aho]] – yIPO <br />
**[[6aho]] – yIPO <br />
 +
**[[8h5b]] – yIPO + TATA box – Cryo EM<br />
 +
**[[8f0x]] – yIPO + histone H2A.2 + H2B.2 – Cryo EM<br />
 +
**[[8f19]] – yIPO + RANGTP – Cryo EM<br />
*IPO-4
*IPO-4
Line 238: Line 255:
**[[6xte]], [[6xu2]] – hIPO + antipain peptide <br />
**[[6xte]], [[6xu2]] – hIPO + antipain peptide <br />
 +
**[[9im6]] – mIPO NLS-binding domain + RanBP5 peptide – Cryo EM<br />
*IPO-7
*IPO-7
Line 246: Line 264:
**[[6n1z]] – hIPO + histone H2A + histone H2B <br />
**[[6n1z]] – hIPO + histone H2A + histone H2B <br />
 +
**[[8f7a]] – hIPO NLS-binding domain + RanGTP – Cryo EM<br />
*IPO-12 (Transportin-3)
*IPO-12 (Transportin-3)
Line 253: Line 272:
**[[4c0q]], [[4ol0]] – hIPO + GTPase Ran<br />
**[[4c0q]], [[4ol0]] – hIPO + GTPase Ran<br />
**[[6gx9]] – hIPO + CPSF 68<br />
**[[6gx9]] – hIPO + CPSF 68<br />
 +
**[[8cmk]] – hIPO + CIRBP<br />
*IPO-13 (karyopherin 13)
*IPO-13 (karyopherin 13)

Current revision

3D structures of importin

Updated on 18-September-2025

Proteopedia Page Contributors and Editors (what is this?)

Michal Harel, Joel L. Sussman

Personal tools